FDA Trending News

Investigational Pancreatic Cancer Drug Receives Expanded Access From the FDA

Jun 3, 2026

Today, the U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

The expanded access treatment protocol is for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The FDA received the expanded access request from Revolution Medicines on April 28 and signed it on April 30.

FDA regulations allow expanded access to investigational drugs for treatment purposes for larger populations under a treatment protocol or treatment investigational new drug application. Per EAP guidelines, requests for expanded access must be submitted to the sponsor by physicians licensed in the U.S. on behalf of eligible patients.

“Granting the request two days after receiving the expanded access application reflects the FDA’s strong commitment to facilitate early access to therapies for serious and life-threatening conditions, including pancreatic cancer,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Having taken care of many patients with metastatic cancer, I am hopeful that today’s action will improve the lives of patients suffering from this disease.”

Daraxonrasib is a RAS inhibitor designed to inhibit a protein (RAS) that is mutated in most pancreatic cancer tumors.

The company said on April 13 that it intends to submit a new drug application for daraxonrasib under the Commissioner’s National Priority Voucher (CNPV) pilot program. The FDA granted a national priority voucher to daraxonrasib, also called RMC-6236, in October 2025.

The FDA previously granted Breakthrough Therapy and Orphan Drug designations to daraxonrasib.

Source:

U.S. Food and Drug Administration. FDA Permits Expanded Access to Investigational Pancreatic Cancer Drug [Internet]. Silver Spring (MD): FDA; 2026 May 1 [cited 2026 May 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug

Reported by

Reviewed by

You May Also Like

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

,

Muscle weakness is one of the biggest challenges of aging. As people get older, they naturally lose muscle strength and muscle mass, a condition known as sarcopenia. This can make everyday activities like climbing stairs, carrying groceries, or getting up from a chair much more difficult. While exercise and good nutrition remain the best ways to slow muscle loss, researchers are searching for new treatments that target the underlying causes of age-related muscle weakness.

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

, ,

Many people take glucosamine supplements every day to help support their joints. It has been used for years and is one of the most popular supplements for osteoarthritis. However, a new study is raising questions about whether glucosamine could affect brain health in people with Alzheimer’s disease or mild cognitive impairment.

The Facts on Tampons and Tampon Safety

The Facts on Tampons and Tampon Safety

,

Tampons are absorbent products that you insert into your vagina to soak up menstrual flow during your period. Tampons come in different absorbency levels — like light, regular, and super — so you can pick the right one for your flow. Some have a plastic or cardboard applicator to help with insertion, and others are inserted with your finger.